NKT Therapeutics is a biotechnology company organized around development of an immune cell-targeting process: therapeutics targeting NKT cells to treat sickle cell diseases, autoimmune and inflammatory disease, cancer, and asthma. NKT cells--natural killer T cells--are a rare but central component of the immune system that play a pivitol role in human health and disease. By targeting these cells, NKT Therapeutics can develop selective immune modulators with disease-treating potential. As of 2014 NKT's NKTT320 candidate for the treatment of sickle cell diseases had completed dosing in its phase 1b trial. Other candidates were in pre-clinical development for cancer and autoimmune disorders.
